Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either due to the genetic activation of its upstream activating signaling pathways or the genetic inactivation of its negative regulators. The tumor suppressor liver kinase B1 (LKB1), also known as serine/threonine kinase 11 (STK11), is involved in cell polarity, cell detachment and adhesion, tumor metastasis, and energetic stress response. A key role of LKB1 is to negatively regulate the activity of mTOR complex 1 (mTORC1). This review summarizes the molecular basis of this negative interaction and recent research progress in this area.
AMP-Activated Protein Kinases ; metabolism ; Adenocarcinoma ; drug therapy ; metabolism ; Animals ; Antibiotics, Antineoplastic ; therapeutic use ; Disease Models, Animal ; Endometrial Neoplasms ; drug therapy ; metabolism ; Female ; Humans ; Mechanistic Target of Rapamycin Complex 1 ; Multiprotein Complexes ; metabolism ; Phosphatidylinositol 3-Kinases ; metabolism ; Protein-Serine-Threonine Kinases ; metabolism ; Proto-Oncogene Proteins c-akt ; metabolism ; Signal Transduction ; Sirolimus ; therapeutic use ; TOR Serine-Threonine Kinases ; metabolism ; Tumor Suppressor Proteins ; metabolism